miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro

Effectively targeting cancer stem cells, a subpopulation of tumorigenic, aggressive, and radioresistant cells, holds therapeutic promise. However, the effects of the microRNA miR-142-3p, a small endogenous regulator of gene expression on breast cancer stem cells, have not been investigated. This study identifies the influence of miR-142-3p on mammary stemness properties and breast cancer radioresistance to establish its role in this setting. miR-142-3p precursor transfection was performed in MDA-MB-468, HCC1806, and MCF-7 cells, and stem cell markers CD44, CD133, ALDH1 activity and mammosphere formation were measured. β-catenin, the canonical wnt signaling effector protein, was quantified by Western blots and cell fluorescence assays both in miR-142-3p–overexpressing and anti–miR-142-3p–treated cells. Radiation response was investigated by colony formation assays. Levels of BRCA1, BRCA2, and Bod1 in miR-142-3p–overexpressing cells as well as expression of miR-142-3p, Bod1, KLF4, and Oct4 in sorted CD44+/CD24–/low cells were determined by quantitative polymerase chain reaction. miR-142-3p overexpression resulted in a strong decline in breast cancer stem cell characteristics with a decrease in CD44, CD133, ALDH1, Bod1, BRCA2, and mammosphere formation as well as reduced survival after irradiation. miR-142-3p expression was strongly reduced in sorted CD44+/CD24–/low stem cells, while Bod1, Oct4, and KLF4 were overexpressed. β-catenin levels strongly decreased after miR-142-3p overexpression, but not after anti–miR-142-3p treatment. We conclude that miR-142-3p downregulates cancer stem cell characteristics and radioresistance in breast cancer, mediated by a reduced role of β-catenin in miR-142-3p–overexpressing cells. miR-142-3p might therefore help to target cancer stem cells.

[1]  M. Götte,et al.  MicroRNA regulation of proteoglycan function in cancer , 2014, The FEBS journal.

[2]  Jian Jian Li,et al.  The role of radiotherapy-resistant stem cells in breast cancer recurrence. , 2013, Breast cancer management.

[3]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[4]  Alexander M. Many,et al.  Both Canonical and Non-Canonical Wnt Signaling Independently Promote Stem Cell Growth in Mammospheres , 2014, PloS one.

[5]  R. Dulbecco,et al.  The properties of a mammary gland cancer stem cell , 2007, Proceedings of the National Academy of Sciences.

[6]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[7]  Marie-Pier Tétreault,et al.  Krüppel-like factors in cancer , 2013, Nature Reviews Cancer.

[8]  Taichi Isobe,et al.  miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway , 2014, eLife.

[9]  H. Meijers-Heijboer,et al.  Coregulation of FANCA and BRCA1 in human cells , 2014, SpringerPlus.

[10]  Guo-Hui Fu,et al.  MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells , 2013, Journal of Molecular Medicine.

[11]  Y. Shimono,et al.  MicroRNA Regulation of Human Breast Cancer Stem Cells , 2015, Journal of clinical medicine.

[12]  G. Viglietto,et al.  Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs , 2010, Cell cycle.

[13]  Leaf Huang,et al.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.

[14]  M. Smalley,et al.  Breast cancer stem cells: obstacles to therapy. , 2013, Cancer letters.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  V. Vinh-Hung,et al.  Molecular biology of breast cancer stem cells: potential clinical applications. , 2010, Cancer treatment reviews.

[17]  M. Khazaei,et al.  New Findings on Breast Cancer Stem Cells: A Review , 2015, Journal of breast cancer.

[18]  V. Yang,et al.  Krüppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. , 2005, Oncogene.

[19]  S. Majumder,et al.  Emerging role of microRNAs in drug-resistant breast cancer. , 2011, Gene expression.

[20]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[21]  Qin Li,et al.  Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer , 2015, Diagnostic Pathology.

[22]  Carlos Caldas,et al.  Alpha‐6 integrin is necessary for the tumourigenicity of a stem cell‐like subpopulation within the MCF7 breast cancer cell line , 2008, International journal of cancer.

[23]  Yi-Wei Chen,et al.  MicroRNA142-3p Promotes Tumor-Initiating and Radioresistant Properties in Malignant Pediatric Brain Tumors , 2014, Cell transplantation.

[24]  Paolo Peterlongo,et al.  Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR‐103 target site , 2012, Human mutation.

[25]  Björn Kemper,et al.  microRNA miR-142-3p Inhibits Breast Cancer Cell Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and Additional Cytoskeletal Elements , 2015, PloS one.

[26]  Xiaoman Li,et al.  Radiation induces premature chromatid separation via the miR-142-3p/Bod1 pathway in carcinoma cells , 2016, Oncotarget.

[27]  Martin Götte,et al.  Flow cytometry in cancer stem cell analysis and separation , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[28]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature reviews genetics.

[29]  Libing Song,et al.  Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. , 2012, Journal of molecular cell biology.

[30]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[31]  M. Lleonart,et al.  MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. , 2013, Cancer letters.

[32]  Andrew J. Bannister,et al.  The putative tumour suppressor Fus-2 is an N-acetyltransferase , 2000, Oncogene.

[33]  G. Landberg,et al.  Wnt Pathway Activity in Breast Cancer Sub-Types and Stem-Like Cells , 2013, PloS one.

[34]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[35]  Thierry Emonet,et al.  Adaptability of non-genetic diversity in bacterial chemotaxis , 2014, eLife.

[36]  B. Kemper,et al.  Survivin, a target to modulate the radiosensitivity of Ewing’s sarcoma , 2012, Strahlentherapie und Onkologie.

[37]  W. Fan,et al.  Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics , 2016, Molecular medicine reports.

[38]  N. Wong,et al.  Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133 , 2014, Oncotarget.

[39]  Jinming Yu,et al.  A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy , 2017, Breast Cancer Research and Treatment.

[40]  N. Villegas-Sepúlveda,et al.  Tumor suppressor miR-29c regulates radioresistance in lung cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[41]  Yue Yu,et al.  miR‐142‐3p inhibits cancer cell proliferation by targeting CDC25C , 2016, Cell proliferation.

[42]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[43]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  David A Hess,et al.  High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability , 2009, Journal of cellular and molecular medicine.

[45]  Wei Zhang,et al.  MicroRNA-142-3p Negatively Regulates Canonical Wnt Signaling Pathway , 2016, PloS one.

[46]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[47]  MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1 , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[48]  S. Nam,et al.  Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53 , 2015, Cell Death and Disease.

[49]  Hui Wang,et al.  CD44+/CD24− phenotype predicts a poor prognosis in triple-negative breast cancer , 2017, Oncology letters.

[50]  L. Tume,et al.  CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy , 2016 .